Graves' disease: high NLR predicts relapse after antithyroid drug therapy

  • Kim M & al.
  • Endocrine
  • 20.11.2019

  • von Brian Richardson, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • A high neutrophil-to-lymphocyte ratio (NLR) is associated with relapse in patients with Graves' disease treated with antithyroid drug (ATD) therapy.

Why this matters

  • Prognostic markers can help guide patient management, and the NLR is simple, noninvasive, and cost-effective.

Key results

  • 21% of patients experienced relapse within a year of ATD withdrawal.
  • Patients with high NLR (≥1.14) had shorter relapse-free survival (RFS) compared with patients with low NLR (
  • High NLR was associated with an increased risk for relapse compared with low NLR in multivariate analysis (OR, 4.22; P=.016).
  • Young age at the time of diagnosis was also associated with risk for relapse (OR, 4.20; P=.017).

Study design

  • 108 patients with Graves' disease who received ATD therapy were analyzed for relapse/RFS and associated factors.
  • Funding: None disclosed.

Limitations

  • Retrospective study.